Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT01244854 Completed - Schizophrenia Clinical Trials

Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness

Start date: October 1, 2010
Phase: N/A
Study type: Interventional

Persons with serious mental illness are at increased risk of cardiovascular disease. The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and to get feedback from patients and providers on what is needed to help better coordinate and physical and mental health care of these patients.

NCT ID: NCT01243957 Completed - Clinical trials for Major Depressive Disorder

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together. This study will look at how fluoxetine might affect LY2216684 and how giving LY2216684 might affect fluoxetine in the body. The duration of study participation in this study is approximately 36 days not including the screening appointment. This study requires 1 research unit confinement of 29 days/28 nights followed by 1 outpatient appointment. A screening appointment is required within 30 days prior to the start of the study.

NCT ID: NCT01241435 Completed - Clinical trials for Depressive Disorder, Major

A Study of LY2216684 in Participants With Impaired Hepatic Function

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The duration of participation in this study is approximately 12 days, not including the screening visit. This study requires 1 clinic confinement of 5 days/4 nights followed by 1 out-patient follow-up visit. A screening visit is required within 30 days prior to the start of the study. This research study will be an open-label study. The study involves a single oral dose of 18 milligrams (mg) LY2216684 given as 2 tablets.

NCT ID: NCT01240083 Completed - Depression Clinical Trials

Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression

Start date: April 2010
Phase: N/A
Study type: Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) as well as Theta- Burst Stimulation of the frontal cortex are used to modulate the neuronal excitability in patients with depression. In the proposed study we investigate whether high frequent rTMS or Theta-Burst Stimulation of the DLPFC is more effective in patients with a depressive episode.

NCT ID: NCT01238614 Completed - Maternal Depression Clinical Trials

Universal Screening for Maternal Depression With the CHICA System

Start date: October 2007
Phase: N/A
Study type: Interventional

The CHICA system is a clinical decision support system that uses adaptive turnaround documents to provide point-of-care information to clinicians. We will be studying whether it can help in the diagnosis and referral of mothers with maternal depression.

NCT ID: NCT01235533 Completed - Clinical trials for Late-Life Depression

Fish Oil Supplementation in Late-life Depression

Start date: May 2007
Phase: N/A
Study type: Interventional

To investigate whether fish oil supplementation, compared to placebo (olive oil), could have better effects on depression course and cognitive function in older people with major depression.

NCT ID: NCT01234558 Completed - Clinical trials for Major Depressive Disorder

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

NCT ID: NCT01223677 Completed - Depression Clinical Trials

Rumination-focused CBT Training for the Prevention of Depression and Anxiety

Start date: October 2010
Phase: Phase 1
Study type: Interventional

Depression and anxiety disorders are highly prevalent and associated with reduced quality of life for patients and enormous economic costs for society. Although effective treatments are available, a substantial number of patients fail to respond, and the time between disorder onset and treatment is typically long. The development of prevention programs therefore appears promising. The current project aims to prevent depression and anxiety by targeting excessive levels of worry and rumination, two important risk factors for emotional disorders. Participants will be selected on the basis of a high score on two validated questionnaires on worry and rumination. They will be randomly assigned to a rumination-focused cognitive-behavioral training delivered in a group format, a rumination-focused cognitive-behavioral training delivered via internet, or a no-training control condition. It is expected that both versions of the rumination-focused training will reduce symptoms of depression and anxiety, will reduce the incidence of major depressive episodes and generalized anxiety disorder, and will reduce symptom levels of other emotional disorders.

NCT ID: NCT01221935 Completed - Clinical trials for Major Depressive Disorder

Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

Start date: September 2009
Phase: Phase 4
Study type: Observational

The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for major depressive disorder (MDD).

NCT ID: NCT01221701 Completed - Clinical trials for Depressive Disorder in Mothers

Treatment of Depression in Mothers in Home Visitation

MIDIS
Start date: October 2006
Phase: N/A
Study type: Interventional

This study develops and contrasts In-Home Cognitive Behavioral Therapy (IH-CBT), an adapted evidence-based treatment for depressed mothers participating in home visitation, with typical home visitation in which treatment may be obtained in the community. Mothers will be identified using a two step process consisting of administration of a screen and subsequent diagnosis of Major Depressive Disorder. The will then be randomized into the treatment and control conditions. A comprehensive assessment of depression and related areas of functioning will be administered at pre-treatment, post-treatment, and 3 month follow-up. It is hypothesized that IH-CBT will lead to broad and durable gains in mood and social support relative to those in typical home visitation.